iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
iPS細胞技術を用いた代表的な神経変性疾患に対する病態モデリングと創薬研究に関する最新の知見を総説としてまとめました。
Abstract: It has been 15 years since the birth of human induced pluripotent stem cell (iPSC) technology in 2007, and the scope of its application has been expanding. In addition to the development of cell therapies using iPSC-derived cells, pathological analyses using disease-specific iPSCs and clinical trials to confirm the safety and efficacy of drugs developed using iPSCs are progressing. With the innovation of related technologies, iPSC applications are about to enter a new stage. This review outlines advances in iPSC modeling and therapeutic development for cardinal neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease.
Author: Hideyuki Okano, Satoru Morimoto
Journal: Cell Stem Cell 2022;29(2):189-208.
投稿者プロフィール

- Instructor
-
Satoru Morimoto, M.D., Ph.D.
Instructor
Keio University, School of Medicine.
Department of Physiology
35 Shinanomachi, Shinjuku-ku
Tokyo, 160-8582, Japan
最新の投稿
ノンドメインブログ2023.08.14ヒトもiPS細胞も養育環境がその後の成長にはカンジン
令和5年度 (FY2023)2023.08.13LONRF2 is a protein quality control ubiquitin ligase whose deficiency causes late-onset neurological deficits
令和5年度 (FY2023)2023.06.04Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery
ノンドメインブログ2023.05.14第二節 神経発生解明への夜明け―これからきっと面白くなる